Latest HNF News
- Pharnext Announces PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A has Been Granted Promising Innovative Medicine (PIM) Designation by UK Medicines and Healthcare Products Regulatory Agency
- Pharnext raises € 7.7 million in a private placement
- ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo; Acceleron to discontinue development of ACE-083.
- The Hereditary Neuropathy Foundation’s Movement is Medicine™ Program Expands to Florida and Continues to Shed Light on the Impact Exercise Has on Charcot-Marie-Tooth (CMT)
- Cannabis & CMT